alexa The impact of hepatitis viruses on chronic lymphoproliferative disorders--preliminary results.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Diabetes & Metabolism

Author(s): Vladareanu AM, Ciufu C, Neagu AM, Onisai M, Bumbea H,

Abstract Share this page

Abstract The aim of this study is to analyze a group of patients with chronic lymphoproliferative disorders associated with B, C, D hepatitis viral infection. This group of chronic lymphoproliferative disordered patients with associated hepatitis viral infection has been diagnosed and monitored in the Hematology Department of the University Emergency Hospital of Bucharest, between December 2007 and January 2009. Our study is meant to observe the influence of the viral infection on clinical and biological evolution of the enrolled patients. The diagnosis of the chronic lymphoproliferative disorder was based on the bone marrow/ lymph node biopsy and flow-cytometry analysis. The positive diagnosis for hepatitis viral infection was established by ELISA serological tests and viremia was performed by TaqMan method at INBI "Matei Bals" Bucharest. The analyzed group is made up of 41 patients, 25/41 (60.97\%) females and 16/41 (39.02\%) males, with ages: 20-50 years old--6/41 (14.63\%), 51-70 years old--23/41 (56.09\%) and over 71 years old--12/41 (29.26\%) patients. The histological types of CLD: B-cell non-Hodgkin's lymphoma--in 28/41 (68.29\%) patients, T-cell non-Hodgkin's lymphoma--2/41 (4.87\%) patients, Hodgkin's lymphoma--2/41 (4.87\%), chronic lymphocytic leukemia--7/41 (17.07\%), Waldenström disease--2/41 (4.87\%) patients. Regarding the type of CLD, 19/41 (46.34\%) of the patients have an aggressive type of CLD and 22/41 (53.65\%) a non-aggressive type of CLD. The hepatitis viral infection distribution in our patients: 14/41 (34.14\%) have HBV infection, 24/41 (58.53\%) have HCV infection, double/triple association of viral infection was found in 3/41 (7.31\%) patients. Within HBV infection subgroup 9/14 (64.28\%) patients have an aggressive type of CLD and 5/14 (35,71\%) patients have a non-aggressive type, whereas within the group with HCV infection we found a different distribution: 9/24 (37,5\%) patients with aggressive type and 15/24 (62.5\%) with non-aggressive type of CLD. The clinical parameters monitored were: B signs were present in 19/41 (43.34\%) patients, the superficial or profound adenopathies--were found in 29/41 (70,73\%) patients, hepatomegaly--in 38/41 (92,68\%) patients, splenomegaly--in 21/41 (51.21\%) patients, extra-nodal involvements in 10/41 (24,39\%) patients and most frequent in the non-aggressive type of CLD--6/10 (60\%) patients. The hematological and biochemical parameters were: the presence of anemia and thrombocytopenia--found in a small number of patients; lymphocytosis--positive in 33/41 (80.48\%) patients, most with HCV infection and non-aggressive type of disease, the presence of autoimmune hemolytic anemia--in 4/41 (9.75\%) patients, cryoglobulins--8/41 (19.51\%) patients, all with HCV infection; also the liver function was monitored. Antiviral therapy was administered to 12/41 (29.26\%) patients--Lamivudine to 8/41 (19.51\%) patients and Ribavirine/Interferon to 4/41 (9.75\%) patients. Chemotherapy was given in 32/41 (78\%) patients. Monoclonal antibodies anti CD20 (Rituximab) therapy was associated in 6/41 (14.63\%) patients. CONCLUSIONS: A high incidence in female sex of over 50 years old was noticed. A strong association between B-cell chronic lymphoproliferative disorders and hepatitis viral infection B, C, D was revealed, the most frequent being the C hepatitis virus, associated with the non-aggressive type of CLD, extra-nodal involvement, splenomegaly, lymphocytosis, cryoglobulins, cytolysis and colestasis. The clinical and biological disease history will be monitored during chemotherapy and antiviral treatment.
This article was published in J Med Life and referenced in Journal of Diabetes & Metabolism

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords